Open Access. Powered by Scholars. Published by Universities.®

Digital Commons Network

Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences

Research outputs 2014 to 2021

2018

Biomarker

Articles 1 - 2 of 2

Full-Text Articles in Entire DC Network

A Diagnostic Autoantibody Signature For Primary Cutaneous Melanoma, Pauline Zaenker, Johnny Lo, Robert L. Pearce, Phillip Cantwell, Lester Cowell, Mark Lee, Christopher Quirk, Henry Law, Elin S. Gray, Mel R. Ziman Dr Jan 2018

A Diagnostic Autoantibody Signature For Primary Cutaneous Melanoma, Pauline Zaenker, Johnny Lo, Robert L. Pearce, Phillip Cantwell, Lester Cowell, Mark Lee, Christopher Quirk, Henry Law, Elin S. Gray, Mel R. Ziman Dr

Research outputs 2014 to 2021

Melanoma is an aggressive form of skin cancer that is curable by surgical excision in the majority of cases, if detected at an early stage. To improve early stage melanoma detection, the development of a highly sensitive diagnostic test is of utmost importance. Here we aimed to identify antibodies to a panel of tumour associated antigens that can differentiate primary melanoma patients and healthy individuals. A total of 245 sera from primary melanoma patients and healthy volunteers were screened against a high-throughput microarray platform containing 1627 functional proteins. Following rigorous statistical analysis, we identified a combination of 10 autoantibody biomarkers …


Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive And Personalised Medicine, Alyce Russell, Eric Adua, Ivo Ugrina, Simon Laws, Wei Wang Jan 2018

Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive And Personalised Medicine, Alyce Russell, Eric Adua, Ivo Ugrina, Simon Laws, Wei Wang

Research outputs 2014 to 2021

Multiple factors influence immunoglobulin G glycosylation, which in turn affect the glycoproteins’ function on eliciting an anti-inflammatory or pro-inflammatory response. It is prudent to underscore these processes when considering the use of immunoglobulin G N-glycan moieties as an indication of disease presence, progress, or response to therapeutics. It has been demonstrated that the altered expression of genes that encode enzymes involved in the biosynthesis of immunoglobulin G N-glycans, receptors, or complement factors may significantly modify immunoglobulin G effector response, which is important for regulating the immune system. The immunoglobulin G N-glycome is highly heterogenous; however, it is …